At a glance
- Originator LEO Pharma
- Class Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant hypercalcaemia; Osteitis deformans
Most Recent Events
- 25 Jul 2001 Discontinued-II for Malignant hypercalcaemia in European Union (IV)
- 25 Jul 2001 Discontinued-II for Malignant hypercalcaemia in European Union (PO)
- 25 Jul 2001 Discontinued-II for Osteitis deformans in European Union (PO)